

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM650987

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PhaseBio Pharmaceuticals, Inc.		03/19/2020	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	SILICON VALLEY BANK		
Street Address:	3003 TASMAN DRIVE		
City:	SANTA CLARA		
State/Country:	CALIFORNIA		
Postal Code:	95054		
Entity Type:	Corporation: CALIFORNIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	88847647	PB PHASEBIO	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(619) 699-2708		
Email:	christian.cruz@us.dlapiper.com		
Correspondent Name:	DLA Piper LLP (US)		
Address Line 1:	401 B Street		
Address Line 2:	Suite 1700		
Address Line 4:	San Diego, CALIFORNIA 92101		
NAME OF SUBMITTER:	Matt Schwartz		
SIGNATURE:	/s/ Matt Schwartz		
DATE SIGNED:	06/01/2021		
Total Attachments: 10			
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page1.tif			
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page2.tif			
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page3.tif			
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page4.tif			

CH \$40.00 88847647

source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page5.tif
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page6.tif
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page7.tif
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page8.tif
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page9.tif
source=PhaseBio Pharmaceuticals, Inc.- Revised IPSA (05-21)#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (“**Agreement**”) is entered into as of March 19, 2020, by and among (a) **SILICON VALLEY BANK**, a California corporation (“**SVB**”), in its capacity as administrative agent and collateral agent (“**Agent**”), (b) SVB as a lender, (c) **WESTRIVER INNOVATION LENDING FUND VIII, L.P.**, a Delaware limited partnership (“**WestRiver**”), as a lender (SVB and WestRiver and each of the other “Lenders” from time to time a party hereto are referred to herein collectively as the “**Lenders**” and each individually as a “**Lender**”), and (d) **PHASEBIO PHARMACEUTICALS, INC.**, a Delaware corporation (“**Grantor**”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Lenders and Grantor dated as of March 25, 2019 (as the same may be amended, modified or supplemented from time to time, including, without limitation, by that certain Consent to Loan and Security Agreement dated as of April 10, 2019, and that certain First Amendment to Loan and Security Agreement dated as of the same date hereof, collectively, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent, for the ratable benefit of Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.

3. Authorization. Grantor hereby authorizes Agent, on behalf of the Lenders, to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent, on behalf of the Lenders, with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., “pdf” or “tif” format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address:

PHASEBIO PHARMACEUTICALS, INC.

1 Great Valley Parkway, Suite 30
Malvern, PA 19355
Attn: CEO

By:  _____

Name: Jonathan Mow

Title: Chief Executive Officer

{Signature Page to Intellectual Property Security Agreement}

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

AGENT:

Address:

SILICON VALLEY BANK

3475 Piedmont Road, Suite 560
Atlanta, GA 30305
Attn: Myron Jensen

By: Thomas F Gordon

Name: THOMAS F GORDON

Title: MANAGING DIRECTOR

LENDER:

Address:

SILICON VALLEY BANK

3475 Piedmont Road, Suite 560
Atlanta, GA 30305
Attn: Myron Jensen

By: Thomas F Gordon

Name: THOMAS F GORDON

Title: MANAGING DIRECTOR

[Signature Page to Intellectual Property Security Agreement]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

LENDER:

Address:

**WESTRIVER INNOVATION LENDING
FUND VIII, L.P.**

c/o WestRiver Management, LLC
920 5th Avenue, Floor 34, Suite 3450
Seattle, WA 98104
Attn: Doug Hollenbeck or Harper Ellison

By:  _____

Name: Trent Dawson

Title: Chief Financial Officer

[Signature Page to Intellectual Property Security Agreement]

**TRADEMARK
REEL: 007312 FRAME: 0494**

EXHIBIT A

Copyrights

Description

Registration/
Application
Number

Registration/
Application
Date

None

EXHIBIT B

Patents

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Modified vasoactive intestinal peptides	9029505	05/12/2015
Use of modified vasoactive intestinal peptides in the treatment of hypertension	9561262	02/07/2017
Modified vasoactive intestinal peptides	9700598	07/11/2017
A method for administering a sustained release formulation	9919032	03/20/2018
Use of modified vasoactive intestinal peptides in the treatment of hypertension	10940182	03/09/2021
Methods and compositions for treating cystic fibrosis	15308626	11/03/2016
ELP fusion proteins for controlled and sustained release	1072590	07/28/2020
Methods and compositions for treating muscle disease and disorders	10688156	06/23/2020
Modified vasoactive intestinal peptides	15621320	06/13/2017
ELP fusion proteins for controlled and sustained release	16099261	11/06/2018
Metalloenzyme inhibitor compounds	16124846	09/07/2018
ELP fusion proteins for controlled and sustained release	16939624	07/27/2020
Methods and compositions for treating muscle disease and disorders	16907759	6/22/2020
Methods of treatment of hypertension with VIP-ELP fusion polypeptides	63131491	12/29/2020
Methods of reversing ticagrelor activity	17278075	09/20/2019
Vasoactive intestinal peptide fusion proteins for the treatment of COVID-19	63032244	05/29/2020
Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody	63186515	05/10/2021
Metalloenzyme inhibitor compounds	10538511	01/21/2020
Metalloenzyme inhibitor compounds	16746098	01/17/2020

EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
PHASEBIO	88107576	09/06/2018
PB PHASEBIO [Design]	88847647	03/25/2020

EXHIBIT D

Mask Works

Description

Registration/
Application
Number

Registration/
Application
Date

None

294465671.1
354271-000840